Summary: Researchers have launched the first clinical trial at the University of Southern California to test whether structured mindfulness training can enhance and prolong the therapeutic effects of psilocybin-assisted therapy. The study combines rigorous clinical methods with extensive biological and neuroimaging assessments to map how these interventions change brain function, inflammation markers, and cognitive flexibility.
The randomized eight-week trial will enroll about 72 healthy, psychedelic-naive, middle-aged adults from the Los Angeles area. Participants will receive supervised psilocybin-assisted therapy either alone or together with a formal mindfulness meditation program. The investigators will collect longitudinal data across multiple biological systems to identify the mechanisms that underlie change and resilience.
Using a comprehensive battery that includes fMRI, EEG, blood and saliva biomarkers, stool microbiome profiles, and behavioral and cognitive testing, the multidisciplinary team aims to chart the biological pathways involved in self-processing, inflammation, and neural plasticity. The ultimate goal is to inform personalized, rapid-acting behavioral health interventions grounded in objective measures as well as subjective outcomes.
Key Facts
- USC’s Psychedelic Debut: This is the first psychedelic-assisted therapy study conducted at USC, marking a notable institutional investment in novel mental health approaches.
- The Mindfulness Synergy: Investigators propose that mindfulness meditation provides practical cognitive tools to weaken maladaptive personal narratives, a process that psilocybin may accelerate and help consolidate.
- ARPA-H EVIDENT Backing: The study is funded through ARPA-H’s EVIDENT program, which supports rapid, data-driven advances in behavioral health.
- The 72-Participant Baseline: To isolate core mechanisms, the trial enrolls 72 adults without prior psychedelic or formal meditation experience and without current psychiatric or medical disorders.
- Deep Biological Deep Dive: The protocol goes beyond self-report by integrating blood, saliva, stool, EEG, and functional MRI assessments to capture multi-system responses.
- Tracking Narrative Networks: Neuroimaging will focus on changes in the brain’s default mode network (DMN) and circuits linked to self-narrative processing and cognitive control.
- One-Year Longevity Check: Participants will complete structured follow-up assessments at three months, six months, and one year to measure the persistence of cognitive, emotional, and spiritual changes.
Source: USC
Researchers at the Keck School of Medicine, the Brain and Creativity Institute, and the USC Norris Comprehensive Cancer Center have initiated USC’s first clinical trial of psychedelic-assisted therapy.
The investigation centers on psilocybin, the active compound in certain mushrooms, which has shown preliminary promise for treating conditions such as substance use disorders and depression. By recruiting healthy community volunteers, the research team aims to determine whether adding structured mindfulness training can increase therapeutic benefit and durability when combined with psilocybin-assisted sessions.
Funded in part by the Advanced Research Projects Agency for Health (ARPA-H) through its Evidence-Based Validation & Innovation for Rapid-Acting Treatments (EVIDENT) initiative, the study is designed to accelerate the development of more effective, personalized behavioral health treatments using detailed, real-time clinical and biological data.
The trial is co-led at USC by Rael Cahn, MD, PhD, director of the USC Center for Mindfulness Science and clinical associate professor of psychiatry and behavioral sciences, and Caryn Lerman, PhD, director of the USC Norris Comprehensive Cancer Center and Distinguished Professor of Psychiatry and Behavioral Sciences. The work will take place at Cahn’s lab within the USC Brain and Creativity Institute, in collaboration with other investigators across USC focused on music, neuroimaging, and psychology.
Psilocybin and mental health
Psilocybin produces profound shifts in perception, mood, and cognition. When administered with therapeutic support, it can occasion meaningful, sometimes spiritual experiences that appear to influence behavior and well-being. Although psilocybin remains a Schedule I substance under U.S. law, the FDA has granted it breakthrough therapy status for major depressive disorder and treatment-resistant depression, reflecting emerging evidence of substantial clinical potential. Research has also suggested promise for addiction treatment.
“Psilocybin-assisted therapy has the potential to change how we approach mental health research,” said Caryn Lerman. “These treatments may offer benefits not only for addiction and mood disorders but also for improving quality of life for people with serious illness. This study enables rigorous investigation and contributes valuable data to a broader national effort.”
Participants will be randomized to receive either psilocybin-assisted therapy alone under supervision or psilocybin combined with an eight-week mindfulness meditation curriculum. Mindfulness is a structured approach that trains attention and awareness through regular meditative practices; prior research links it to broad mental and physical health benefits. The central hypothesis is that practicing mindfulness during a window of heightened neuroplasticity induced by psilocybin may strengthen and prolong positive changes.
Evaluation with comprehensive data
The study will enroll approximately 72 middle-aged adults from Los Angeles who have no active psychiatric or medical disorders and no previous psychedelic or meditation experience. The open-label trial will provide psilocybin-assisted therapy within a structured clinical protocol at the USC Brain and Creativity Institute. All participants will complete a thorough set of assessments, including EEG, MRI/fMRI, blood and saliva sampling, stool collection for microbiome analysis, and psychological and cognitive testing before and after treatment.
Follow-up evaluations at roughly three months, six months, and one year will track psychological well-being, spirituality, cognitive function, brain activity related to self and narrative processing, and biological markers tied to inflammation and brain health. By combining objective biomarkers with subjective outcome measures, the team hopes to identify signatures of durable therapeutic change.
“Mindfulness teaching gives people practical tools to notice and change unhelpful narratives,” said Rael Cahn. “Paired with psilocybin, those practices may help lock in structural and functional brain changes, producing longer-lasting benefits.”
About the study
Supported by ARPA-H’s EVIDENT program, the study contributes de-identified digital, neural, and biological data to a secure national repository to enable cross-study modeling of rapid mental health recovery. ARPA-H, an agency within the U.S. Department of Health and Human Services, supports high-impact research intended to transform health outcomes through bold innovation.
Funding: This research was funded, in part, by the Advanced Research Projects Agency for Health (ARPA-H). The views and conclusions presented are those of the authors and do not necessarily reflect the official policies of the U.S. Government.
Key Questions Answered:
A: Studying healthy, medication-free volunteers allows scientists to observe the brain’s baseline responses without the confounding effects of active disease, co-occurring medications, or variable symptom courses. This cleaner baseline helps researchers map direct biological and neural effects of psilocybin and mindfulness, which can guide later clinical trials in specific patient populations.
A: EVIDENT (Evidence-Based Validation & Innovation for Rapid-Acting Treatments) is an ARPA-H program that supports rapid behavioral health research using detailed clinical, neural, and biological data. De-identified data from this study—such as genetic markers, brain imaging, and microbiome profiles—will be contributed to a secure national repository to enable large-scale analyses across multiple studies.
A: Psilocybin appears to open a window of increased neuroplasticity when the brain is more receptive to change. Without deliberate practice, that window may close and old patterns can return. Mindfulness training supplies explicit, repeatable skills for observing and reframing unhelpful thoughts and narratives. When those skills are taught and practiced during or shortly after psilocybin-induced plasticity, they may help direct and stabilize new cognitive and behavioral patterns for the long term.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by staff.
About this psychedelics and neuroscience research news
Author: Laura LeBlanc
Source: USC
Contact: Laura LeBlanc – USC
Image: The image is credited to Neuroscience News